INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 448m ago
HOUSE PTR48m ago
SEC 13F48m ago
ROBINHOOD CHAIN48m ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Riker Lauren sold PCRX

Senior Vice President, Finance · Pacira BioSciences, Inc. · Common Stock

Side
SELL
Value
$218K
Shares
6,000
Price
$36.32
Executed
Oct 8, 2026
Disclosed
Oct 9, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Oct 8 executedOct 9, 2026 disclosed

PCRX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
12/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+8 / 25

    $218K reported value · 8.8% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · PCRX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    6
    RL
    Riker LaurenSenior Vice President, Finance
    PCRXPacira BioSciences, Inc.
    Option exercise · 10b5-1 plan
    		M$194K
    6,000 sh
    		Oct 8, 2026Oct 9, 2026
    traded Oct 8, 2026
    		+1dSEC FORM 4

    Evidence

    0
    RL
    Riker LaurenSenior Vice President, Finance
    PCRXPacira BioSciences, Inc.
    Option exercise · 10b5-1 plan
    		M—
    6,000 sh
    		Oct 8, 2026Oct 9, 2026
    traded Oct 8, 2026
    		+1dSEC FORM 4

    Evidence

    0
    CS
    Cross ShawnChief Financial Officer
    PCRXPacira BioSciences, Inc.
    Option exercise · 10b5-1 plan
    		M—
    2,845 sh
    		Apr 21, 2026Apr 22, 2026
    traded Apr 21, 2026
    		+1dSEC FORM 4

    Evidence

    6
    CS
    Cross ShawnChief Financial Officer
    PCRXPacira BioSciences, Inc.
    Option exercise · 10b5-1 plan
    		M$127K
    7,714 sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    4
    CS
    Cross ShawnChief Financial Officer
    PCRXPacira BioSciences, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$71K
    2,845 sh
    		Apr 21, 2026Apr 22, 2026
    traded Apr 21, 2026
    		+1dSEC FORM 4

    Evidence

    0
    CS
    Cross ShawnChief Financial Officer
    PCRXPacira BioSciences, Inc.
    Option exercise · 10b5-1 plan
    		M$25K
    1,500 sh
    		Apr 22, 2026Apr 22, 2026
    traded Apr 22, 2026
    		+0dSEC FORM 4

    Evidence

    1
    CS
    Cross ShawnChief Financial Officer
    PCRXPacira BioSciences, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$38K
    1,500 sh
    		Apr 22, 2026Apr 22, 2026
    traded Apr 22, 2026
    		+0dSEC FORM 4

    Evidence

    0
    CS
    Cross ShawnChief Financial Officer
    PCRXPacira BioSciences, Inc.
    Option exercise · 10b5-1 plan
    		M—
    7,714 sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    12
    CS
    Cross ShawnChief Financial Officer
    PCRXPacira BioSciences, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$194K
    7,714 sh
    		Apr 20, 2026Apr 22, 2026
    traded Apr 20, 2026
    		+2dSEC FORM 4

    Evidence

    0
    CS
    Cross ShawnChief Financial Officer
    PCRXPacira BioSciences, Inc.
    Option exercise · 10b5-1 plan
    		M—
    1,500 sh
    		Apr 22, 2026Apr 22, 2026
    traded Apr 22, 2026
    		+0dSEC FORM 4

    Evidence

    0
    CS
    Cross ShawnChief Financial Officer
    PCRXPacira BioSciences, Inc.
    Option exercise · 10b5-1 plan
    		M$47K
    2,845 sh
    		Apr 21, 2026Apr 22, 2026
    traded Apr 21, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001628280-26-065566
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 8, 2026
    Published
    Oct 9, 2026
    Ingested by INSIDER
    Nov 5, 02:12 UTC
    Last re-read
    Nov 5, 02:12 UTC

    Extracted facts

    Filer
    Riker Lauren
    Role
    Senior Vice President, Finance
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Pacira BioSciences, Inc.
    Ticker
    PCRX
    Shares
    6,000
    Price per share
    $36.32
    Value
    $217,920
    Execution date (reported)
    Oct 8, 2026
    Owned after transaction
    62.3K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 6,000
    • Price: $36.32

    = $217,920

    What this establishes

    Riker Lauren filed this Form 4 reporting a open-market sale of PCRX on Oct 8, 2026. It became public on Oct 9, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Senior Vice President, Finance
    Riker Laurencik:0001545439
    Issuer
    Pacira BioSciences, Inc.cik:0001396814

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.